Skip to Content

WPI 845 (Glipizide Extended Release 10 mg)

Pill with imprint WPI 845 is White, Round and has been identified as Glipizide Extended Release 10 mg. It is supplied by Watson Laboratories, Inc..

Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 10 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 845

Glipizide extended release 10 mg WPI 845
Glipizide extended release 10 mg WPI 845  Front
Glipizide extended release 10 mg WPI 845  Back
Glipizide extended release 10 mg WPI 845  Front
Glipizide extended release 10 mg WPI 845  Back
Glipizide extended release 10 mg WPI 845
Glipizide extended release 10 mg WPI 845

Glipizide Extended Release

Imprint:
WPI 845
Strength:
10 mg
Color:
White
Size:
6.00 mm
Shape:
Round
Availability:
Prescription only
Drug Class:
Sulfonylureas
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Watson Laboratories, Inc.
Inactive Ingredients:
acetyltributyl citrate
hydroxyethyl cellulose (2000 mpa.s at 1%)
hydroxypropyl cellulose (type h)
lactose monohydrate
magnesium stearate
methacrylic acid - methyl methacrylate copolymer (1:1)
polyethylene glycol
shellac
isopropyl alcohol
ferrosoferric oxide
butyl alcohol
propylene glycol
ammonia
Note: Inactive ingredients may vary.

Other Labelers / Repackagers:

NDC CodeLabeler / Repackager
68084-0112 Amerisource Health Services
10370-0191 Anchen Pharmaceuticals, Inc.
54569-5548 A-S Medication Solutions, LLC (repackager)
54868-4988 Physicians Total Care Inc. (repackager)
55289-0301 PDRX Pharmaceuticals Inc. (repackager)

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide